What ChondroFiller costs for a hip injection

Guide costs for a ChondroFiller hip injection in the UK follow a fixed three-tier structure published by specialist clinics: one box approximately £3,000, two boxes approximately £5,500, and three boxes approximately £8,000. These are all-inclusive figures — each price covers the initial consultation, pre-procedure imaging review, the collagen scaffold implant itself, ultrasound-guided placement, IV antibiotic cover, and a six-week follow-up appointment. There are no separately itemised charges on the day of treatment.

For the hip joint specifically, most procedures sit towards the upper end of this range. Because the hip is a deeper, multi-compartment joint with a larger articular surface than most other joints, it typically requires more collagen volume than a straightforward presentation elsewhere. Specialist clinics indicate a broader indicative range of approximately £6,500–£9,500 for hip procedures — though this should be understood as a guide rather than a firm quote, since the exact volume depends on the size and location of the cartilage defect as shown on pre-procedure imaging.

The number of boxes required — and therefore the total cost — is confirmed at an imaging review before any appointment is booked. A clinic quoting without first reviewing the MRI is effectively quoting blind; accurate box-volume assessment requires seeing the scans. For patients, this means the financial picture is clear well in advance, with no open-ended surprises at the time of injection.

Why ChondroFiller costs more than a standard hip injection

The price gap between ChondroFiller and a standard hip injection reflects what the two treatments actually are, rather than a difference in clinic fees.

Corticosteroid injections dampen inflammation for an acute hip flare; hyaluronic acid adds temporary lubrication to the joint. Both are small-molecule injectates regulated at a lower tier. ChondroFiller is a fundamentally different class of product: a CE-marked Class III medical device — the highest-risk regulatory category under European medical device law — manufactured by Meidrix Biomedicals GmbH in Germany and imported into the UK under prescription. Class III status is assigned to active implantable devices that interact with the body's biology, not merely manage symptoms.

Once placed under ultrasound guidance into the hip joint, the acellular murine Type I collagen scaffold gels in situ and initiates acellular matrix-induced chondrogenesis — a process by which the patient's own progenitor cells migrate into the scaffold, differentiate, and support the body's own repair processes in the focal cartilage defect. Standard injections do not work through this mechanism and are not subject to the same manufacturing, regulatory certification, or importation requirements.

It is that regulatory and biological distinction — not a mark-up — that accounts for the difference in cost.

How pre-procedure imaging sets your final cost

Before a treatment plan can be confirmed, a pre-procedure MRI of the hip joint is required. The scan maps the size and depth of the focal cartilage defect — the variable that determines how many boxes of ChondroFiller are needed, and therefore where within the guide-cost range the procedure sits. This imaging review is the clinical step that converts an approximate range into a confirmed figure for that individual's hip.

For patients based in Lincolnshire and the wider East Midlands, this part of the process can typically be arranged locally. The pre-procedure MRI does not need to be performed at the treating clinic; a scan from a local facility can be submitted for review, which means the journey to the injection appointment can usually be made just once.

Once the imaging review is complete and the box count agreed, the treatment appointment itself is straightforward. ChondroFiller is placed as an ultrasound-guided outpatient injection — a clinic visit of approximately 30 to 45 minutes, with no general anaesthetic and no overnight hospital admission. There is no surgical incision. The collagen scaffold is delivered under real-time image guidance directly into the focal defect in the hip joint, and patients leave the clinic on the same day.

NHS funding and private medical insurance for ChondroFiller

ChondroFiller is not available on the NHS, and there is currently no pathway for NHS funding of this treatment in Lincolnshire or elsewhere. Patients who proceed do so either through self-funding or private medical insurance (PMI).

For those with PMI, approvals have been reported with Bupa, Aviva, and WPA. The procedure maps to two CCSD codes — W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy) — which your consultant can include in the clinical correspondence sent to your insurer. Coverage terms vary considerably between individual policies, and approval is not guaranteed; some insurers may cover part of the cost but not all.

The critical step is obtaining written pre-authorisation before the appointment is booked. Retrospective claims — where treatment has already taken place — are unlikely to succeed. When contacting your insurer, ask specifically about the CCSD codes listed above and request a decision in writing. Providing a clinical summary that describes the focal hip cartilage defect and the proposed treatment will support the pre-authorisation request.

If coverage is uncertain, the treating clinic can confirm which codes apply to your individual plan ahead of any commitment.

What the clinical evidence shows for the hip joint

Published data across more than 19,000 ChondroFiller cases worldwide show that 70–85% of patients treated for focal cartilage defects achieve meaningful symptom relief at three to five years. For the hip joint specifically, outcome studies using the modified Harris Hip Score (mHHS) record an improvement of approximately 30 points following treatment — a threshold considered clinically meaningful in hip outcome research.

The hip-specific evidence base is smaller than for the knee, and researchers have called for further work on larger patient groups to fully characterise long-term results for acetabular cartilage lesions. The existing global dataset does, however, offer a useful safety reference point: across all treated joints, the complaint rate sits at approximately 0.06% — pointing to a well-tolerated treatment with a consistent record across joint types including the hip. The call for more hip-focused research reflects where the science is heading, not a signal that the cases studied to date have raised concerns.

Two questions that commonly arise at this stage: there is no upper age limit for the treatment pathway, and hip changes described as 'bone on bone' do not automatically exclude a patient from assessment. Suitability turns on the nature and size of the focal cartilage defect — the variable that the pre-procedure MRI establishes on an individual basis.

Accessing ChondroFiller from Lincolnshire

For Lincolnshire patients, the practical starting point is geography. No ChondroFiller hip injection provider has currently been confirmed in Lincolnshire or the East Midlands, which means the injection appointment itself will require travel to a specialist centre. The pre-procedure MRI, however, can typically be arranged with a local or regional imaging provider in Lincolnshire, so most patients make a single journey to the treating clinic — for the injection itself.

The UK's leading provider of ChondroFiller as an outpatient injectable pathway is London Cartilage Clinic, led by Professor Paul Y.F. Lee, who practises on Harley Street. Professor Lee also holds an Honorary Professorship at the University of Lincoln — a direct academic connection between the specialist centre and the Lincolnshire region that is clinically relevant for patients in this area who are considering the treatment.

For patients who are unsure whether ChondroFiller is appropriate for their hip joint, a local assessment is a straightforward first step. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment; the clinical team can advise on ChondroFiller suitability and support the onward referral pathway where appropriate.